| Customization: | Available |
|---|---|
| CAS No.: | 941678-49-5 |
| Formula: | C17h18n6 |
|
Still deciding? Get samples of US$ 50/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Product name: Ruxolitinib
CAS No: 941678-49-5
Ruxolitinib is a Janus kinase (JAK) inhibitor that is primarily used to treat certain types of blood cancers and other conditions related to abnormal immune responses. It selectively inhibits JAK1 and JAK2, enzymes that play a crucial role in the signaling pathways of cytokines and growth factors. By blocking these enzymes, ruxolitinib helps reduce the inflammation and proliferation of abnormal cells that contribute to diseases like myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD). It is a targeted therapy that offers a more specific approach to treatment compared to traditional chemotherapy.
Application and Effect
Ruxolitinib is most commonly used for treating myelofibrosis and polycythemia vera, two types of myeloproliferative disorders. Myelofibrosis is characterized by the abnormal growth of bone marrow cells, leading to fibrosis (scarring) and impaired blood cell production. Polycythemia vera involves the overproduction of red blood cells, increasing the risk of clotting. By inhibiting JAK1 and JAK2, ruxolitinib reduces the signaling that drives the abnormal proliferation of blood cells, thereby improving symptoms and controlling disease progression. In addition to blood cancers, ruxolitinib is also used to treat graft-versus-host disease (GVHD), a condition that can occur after stem cell or bone marrow transplants, where the transplanted immune cells attack the recipient's tissues. By modulating immune responses, ruxolitinib helps reduce the severity of GVHD. The drug has also been studied for other inflammatory and autoimmune conditions, including atopic dermatitis, but its use is limited to conditions where JAK inhibition can be beneficial. Ruxolitinib is often associated with side effects such as infections, anemia, and liver enzyme abnormalities, necessitating regular monitoring during treatment. However, it provides a more targeted and effective option for managing these complex disorders, improving patients' quality of life and survival rates.
Specifications:
| Composition | C17H18N6 |
| Assay | 99% |
| Appearance | White powder |
| CAS No. | 941678-49-5 |
| Packing | Small and bulk |
| Shelf Life | 2 years |
| Storage | Store in cool and dry area |
| Certification | ISO. |
){kind=link}